Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.

Bladder cancer patients receiving radical radiotherapy frequently experience a health-related quality of life (HRQoL) decline during treatment, which recovers within 6 mo such that, on average, subsequent HRQoL is maintained at or above baseline. Adding concomitant 5-fluorouracil/mitomycin C has no significant impact on HRQoL.